8-K: RespireRx Pharmaceuticals Secures $1.8 Million Department of Defense Grant for Spinal Cord Injury Clinical Trial

RespireRx Pharmaceuticals has received a $1.8 million grant from the Department of Defense to fund a Phase 2 clinical trial of its drug CX1739 for improving bladder function in patients with spinal cord injury.

Summary

• RespireRx Pharmaceuticals has been awarded a $1.8 million grant from the Department of Defense to fund a Phase 2 clinical trial for their lead drug candidate, CX1739.
• The trial will be conducted at the Shirley Ryan AbilityLab and will assess the safety and efficacy of CX1739 in improving bladder function and motor activity in individuals with spinal cord injury.
• The grant will be administered by the U.S. Army Medical Research Acquisition Activity and is part of the Congressionally Directed Medical Research Program.
• The clinical trial will be divided into two stages: Phase 2A, which will be an ascending single dose safety and efficacy study, and Phase 2B, which will be a double-blind, placebo-controlled study.
• RespireRx has been allocated $252,200 of the grant to manufacture and formulate the clinical material and update the investigational new drug application.
• The company plans to begin testing in patients by the fourth quarter of 2024.
• The company believes that this research has the potential to represent a breakthrough in the treatment of spinal cord injury.

Sentiment

Score: 8

Explanation: The document is very positive due to the significant grant award, the advancement of a key drug candidate into Phase 2 trials, and the potential for a breakthrough in spinal cord injury treatment. The collaboration with a reputable institution and the non-dilutive funding further enhance the positive sentiment.

Positives

• The $1.8 million grant is non-dilutive funding, meaning it does not require the company to issue new shares.
• The grant allows RespireRx to advance its lead drug candidate, CX1739, into Phase 2 clinical trials for spinal cord injury.
• CX1739 has already completed multiple Phase 1 safety trials and Phase 2 proof of concept trials demonstrating target engagement.
• The company has a strong collaboration with Dr. David Fuller from the University of Florida, who has demonstrated the ability of CX1739 to improve motor nerve activity and muscle function in animal models of SCI.
• The company has a broad patent portfolio for two drug platforms: neuromodulators and pharmaceutical cannabinoids.
• The company has a pipeline of new and repurposed drug products based on their broad patent portfolios.

Negatives

• The press release contains forward-looking statements, which are subject to risks and uncertainties.
• The company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023.
• The company's success is dependent on the results of clinical trials, which are inherently uncertain.

Risks

• The success of the clinical trial is not guaranteed, and the results may not be positive.
• The company may face regulatory hurdles in obtaining approval for CX1739.
• The company may face competition from other companies developing treatments for spinal cord injury.
• The company's financial position is dependent on its ability to raise additional capital.
• The company's forward-looking statements are subject to various risks and uncertainties, including regulatory policies, available cash, research and development results, and market conditions.

Future Outlook

RespireRx plans to begin Phase 2 clinical trials for CX1739 in spinal cord injury patients in the fourth quarter of 2024, with the potential for a breakthrough in SCI treatment. The company also continues to develop its other drug platforms, including GABAkines and pharmaceutical cannabinoids.

Management Comments

• Dr. Sandhu stated that if CX1739 produces the same effects in humans as in animals, it could be a novel treatment for SCI.
• Dr. Arnold Lippa, CEO and CSO of RespireRx, commented that CX1739 has successfully completed multiple Phase 1 safety trials and Phase 2 proof of concept trials demonstrating target engagement.
• Dr. Lippa also stated that the company has begun planning to conduct translational, Phase 2 studies in SCI patients late this year and believes that this research has the potential to represent a breakthrough in the treatment of SCI.

Industry Context

This announcement is significant as it highlights the potential of AMPAkines in treating neurological disorders, specifically spinal cord injury. The collaboration with a leading rehabilitation center like Shirley Ryan AbilityLab and the funding from the Department of Defense underscores the importance of this research. The company is also developing treatments for other neurological disorders such as epilepsy, pain, ADHD, and obstructive sleep apnea, which are areas of high unmet medical need.

Comparison to Industry Standards

• The $1.8 million grant is a significant amount for a Phase 2 clinical trial, indicating strong support for the research.
• The collaboration with Shirley Ryan AbilityLab, a top-ranked rehabilitation hospital, provides a strong foundation for the clinical trial.
• The use of a two-stage Phase 2A and 2B design is a common approach in clinical trials to assess safety and efficacy.
• The company's focus on AMPAkines and GABAkines aligns with current research trends in neuromodulation.
• The company's development of dronabinol for obstructive sleep apnea is a novel approach in a market with no approved drug treatments.
• The company's approach of repurposing existing drugs like dronabinol for new indications is a cost-effective strategy.

Stakeholder Impact

• Shareholders: The grant award is likely to be viewed positively by shareholders, as it reduces the need for dilutive financing and advances a key drug candidate.
• Employees: The grant award may boost employee morale and provide job security.
• Patients: The clinical trial has the potential to provide a new treatment option for individuals with spinal cord injury.
• Research Community: The research may contribute to the understanding of spinal cord injury and the development of new treatments.
• Creditors: The grant award may improve the company's creditworthiness.

Next Steps

• RespireRx will manufacture and formulate the clinical material for the trial.
• The company will update and submit the CX1739 investigational new drug application.
• The company will begin patient testing in the fourth quarter of 2024.
• The company will conduct the Phase 2A and 2B clinical trials at Shirley Ryan AbilityLab.
• The company will continue to develop its other drug platforms, including GABAkines and pharmaceutical cannabinoids.

Key Dates

Keywords

RespireRx Pharmaceuticals, CX1739, Spinal Cord Injury, Clinical Trial, Department of Defense, AMPAkine, Bladder Function, Neuromodulators, GABAkines, Pharmaceutical Cannabinoids, Dronabinol, Shirley Ryan AbilityLab